<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03997760</url>
  </required_header>
  <id_info>
    <org_study_id>SHP655-101</org_study_id>
    <nct_id>NCT03997760</nct_id>
  </id_info>
  <brief_title>A Study of SHP655 (rADAMTS13) in Sickle Cell Disease</brief_title>
  <acronym>RAISE</acronym>
  <official_title>A Phase 1 Randomized, Double-blind, Placebo-controlled, Multicenter, Ascending Dose, Safety and PK/PD Study of SHP655 (rADAMTS13) in Sickle Cell Disease at Baseline Health</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Takeda Development Center Americas, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      SHP655 is a medicine used to treat sickle cell disease (SCD). The main aim of the study is to&#xD;
      measure the safety and tolerability of SHP655 in SCD participants.&#xD;
&#xD;
      Study participants will receive SHP655 or placebo on Day 1. Their SCD will be treated by&#xD;
      their doctor according to their doctor's usual clinical practice.&#xD;
&#xD;
      During the study, participants will be asked to follow-up on 13 days following SHP655 or&#xD;
      placebo administration for safety assessment. Maximum duration of participation is expected&#xD;
      to be about 2 months&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 21, 2019</start_date>
  <completion_date type="Anticipated">November 2, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>From date of signing informed consent up to study completion (up to Day 31)</time_frame>
    <description>An adverse event (AE) is any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this investigational product or medicinal product. An AE can therefore be any unfavorable and unintended sign (including a clinically significant laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not causality is suspected (ICH Guidance E2A 1995). A serious adverse event (SAE) is any untoward clinical manifestation of signs, symptoms or outcomes (whether considered related to investigational product or not and at any dose) which results in death, is life-threatening, requires inpatient hospitalization, prolongation of hospitalization, is an important medical event. Number of participants with AEs and SAEs will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Binding and Inhibitory Antibodies to SHP655</measure>
    <time_frame>From start of study treatment up to study completion (up to Day 31)</time_frame>
    <description>The number of participants will be summarized by dose for binding and inhibitory antibodies to SHP655 and will be reported as AEs. The study completion date is defined as the date on which the last participant in the study completes the final assessments.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incremental Recovery (IR) of ADAMTS13 Activity and ADAMTS13 Antigen</measure>
    <time_frame>Pre-dose, 15 minutes, 1, 3, 8, 24, 72, 120, 168, 216, 288, and 744 hours post-dose</time_frame>
    <description>IR will be estimated for ADAMTS13 activity and ADAMTS13 antigen (ADAMTS13Ag) following SHP655 infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed Maximum Concentration (Cmax) of ADAMTS13 Activity and ADAMTS13 Antigen</measure>
    <time_frame>Pre-dose, 15 minutes, 1, 3, 8, 24, 72, 120, 168, 216, 288, and 744 hours post-dose</time_frame>
    <description>Cmax will be estimated for ADAMTS13 activity and ADAMTS13 antigen (ADAMTS13Ag) following SHP655 infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Cmax (tmax) of ADAMTS13 Activity and ADAMTS13 Antigen</measure>
    <time_frame>Pre-dose, 15 minutes, 1, 3, 8, 24, 72, 120, 168, 216, 288, and 744 hours post-dose</time_frame>
    <description>Tmax will be estimated for ADAMTS13 activity and ADAMTS13 antigen (ADAMTS13Ag) following SHP655 infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Half-Life (t1/2) of ADAMTS13 Activity and ADAMTS13 Antigen</measure>
    <time_frame>Pre-dose, 15 minutes, 1, 3, 8, 24, 72, 120, 168, 216, 288, and 744 hours post-dose</time_frame>
    <description>Terminal half-life (t1/2) will be estimated for ADAMTS13 activity and ADAMTS13 antigen (ADAMTS13Ag) following SHP655 infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Residence Time From Zero to Infinite (MRT0-Inf) of ADAMTS13 Activity and ADAMTS13 Antigen</measure>
    <time_frame>Pre-dose, 15 minutes, 1, 3, 8, 24, 72, 120, 168, 216, 288, and 744 hours post-dose</time_frame>
    <description>MRT0-inf will be estimated for ADAMTS13 activity and ADAMTS13 antigen (ADAMTS13Ag) following SHP655 infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Residence Time From Zero to 72 hours Post-dose (MRT0-72) of ADAMTS13 Activity and ADAMTS13 Antigen</measure>
    <time_frame>Pre-dose, 15 minutes, 1, 3, 8, 24, and 72 hours post-dose</time_frame>
    <description>MRT0-72 will be estimated for ADAMTS13 activity and ADAMTS13 antigen (ADAMTS13Ag) following SHP655 infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC) From Zero to Time of Last Quantifiable Concentration (AUC0-Last) of ADAMTS13 Activity and ADAMTS13 Antigen</measure>
    <time_frame>Pre-dose, 15 minutes, 1, 3, 8, 24, 72, 120, 168, 216, 288, and 744 hours post-dose</time_frame>
    <description>AUC0-last will be estimated for ADAMTS13 activity and ADAMTS13 antigen (ADAMTS13Ag) following SHP655 infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve Time Curve (AUC) From Zero to 72 hours Post-dose (AUC0-72) of ADAMTS13 Activity and ADAMTS13 Antigen</measure>
    <time_frame>Pre-dose, 15 minutes, 1, 3, 8, 24, and 72 hours post-dose</time_frame>
    <description>AUC0-72 will be estimated for ADAMTS13 activity and ADAMTS13 antigen (ADAMTS13Ag) following SHP655 infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC) From Zero to Infinite Time (AUC0-Inf) of ADAMTS13 Activity and ADAMTS13 Antigen</measure>
    <time_frame>Pre-dose, 15 minutes, 1, 3, 8, 24, 72, 120, 168, 216, 288, and 744 hours post-dose</time_frame>
    <description>AUC0-inf will be estimated for ADAMTS13 activity and ADAMTS13 antigen (ADAMTS13Ag) following SHP655 infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic Clearance (CL) of ADAMTS13 Activity and ADAMTS13 Antigen</measure>
    <time_frame>Pre-dose, 15 minutes, 1, 3, 8, 24, 72, 120, 168, 216, 288, and 744 hours post-dose</time_frame>
    <description>Systemic clearance (CL) will be estimated for ADAMTS13 activity and ADAMTS13 antigen (ADAMTS13Ag) following SHP655 infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution at Steady State (Vss) of ADAMTS13 Activity and ADAMTS13 Antigen.</measure>
    <time_frame>Pre-dose, 15 minutes, 1, 3, 8, 24, 72, 120, 168, 216, 288, and 744 hours post-dose</time_frame>
    <description>Vss will be estimated for ADAMTS13 activity and ADAMTS13 antigen (ADAMTS13Ag) following SHP655 infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Von Willebrand Factor:antigen (VWF:Ag)</measure>
    <time_frame>Pre-dose, 15 minutes, 1, 3, 8, 24, 72, 120, 168, 216, 288, and 744 hours post-dose</time_frame>
    <description>Plasma VWF:Ag a PD variable will be observed to evaluate the effect of SHP655 on VWF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Von Willebrand Factor:Ristocetin cofactor activity (VWF:RCo)</measure>
    <time_frame>Pre-dose, 15 minutes, 1, 3, 8, 24, 72, 120, 168, 216, 288, and 744 hours post-dose</time_frame>
    <description>Plasma VWF:RCo a PD variable will be observed to evaluate the effect of SHP655 on VWF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Platelet Count up to Day 31</measure>
    <time_frame>Baseline up to Day 31</time_frame>
    <description>Change from baseline in platelet count up to Day 31 will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Free Hemoglobin</measure>
    <time_frame>Pre-dose, 15 minutes, 1, 3, 8, 24, 72, 120, 168, 216, 288, and 744 hours post-dose</time_frame>
    <description>The correlation of plasma free hemoglobin on SHP655 activity and VWF will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Thrombospondin Levels</measure>
    <time_frame>Pre-dose, 15 minutes, 1, 3, 8, 24, 72, 120, 168, 216, 288, and 744 hours post-dose</time_frame>
    <description>The correlation of plasma free thrombospondin levels on SHP655 activity and VWF will be assessed.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Sickle Cell Disease</condition>
  <arm_group>
    <arm_group_label>SHP655</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with baseline SCD will receive a single intravenous (IV) infusion at one of the 3 dose levels of 40, 80 and 160 International units per kilogram (IU/kg) in a dose escalation manner for 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo matched to SHP655 of the 3 dose levels of 40 IU/kg, 80 IU/kg, and 160 IU/kg as single IV infusion for 14 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHP655</intervention_name>
    <description>Participants will receive SHP655 as a single IV infusion at one of the 3 dose levels of 40 IU/kg, 80 IU/kg, or 160 IU/kg.</description>
    <arm_group_label>SHP655</arm_group_label>
    <other_name>recombinant ADAMTS13</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will receive placebo matched to SHP655 of the 3 dose levels of 40 IU/kg, 80 IU/kg, and 160 IU/kg as single IV infusion.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 to 65 years at the time of signing the informed consent.&#xD;
&#xD;
          -  An understanding, ability, and willingness to fully comply with study procedures and&#xD;
             requirements.&#xD;
&#xD;
          -  Ability to voluntarily provide written, signed, and dated (personally or via a legally&#xD;
             authorized representative) informed consent to participate in the study.&#xD;
&#xD;
          -  Male or female with a documented history of HbSS or HbSβo thalassemia (based on&#xD;
             clinical record of genetic, electrophoresis, or high-performance liquid chromatography&#xD;
             testing).&#xD;
&#xD;
          -  Participant currently taking hydroxyurea must be on a stable dosing for 3 months at&#xD;
             screening.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The participant was diagnosed with acute VOC in the 21 days before dosing on Day 1.&#xD;
&#xD;
          -  The participant has undergone blood transfusion within the last 30 days or blood&#xD;
             transfusion on greater than or equal to (&gt;=) 2 occasions in the last 90 days, at&#xD;
             Screening Visit.&#xD;
&#xD;
          -  The participant has a history of acquired or congenital thrombotic thrombocytopenic&#xD;
             purpura.&#xD;
&#xD;
          -  The participant has serum creatinine level greater than (&gt;) 1.2 milligrams per&#xD;
             deciliter (mg/dL).&#xD;
&#xD;
          -  The participant has alanine transaminase &gt;3* upper limit of normal (based on clinical&#xD;
             laboratory normal range), direct bilirubin level &gt;2 mg/dL, or indirect bilirubin level&#xD;
             &gt;5 mg/dL at the Screening Visit.&#xD;
&#xD;
          -  The participant has a hemoglobin level &lt;5 grams per deciliter (g/dL) at the Screening&#xD;
             Visit.&#xD;
&#xD;
          -  The participant has a platelet count of &lt;100 000/cubic millimeter (mm^3) at the&#xD;
             Screening Visit.&#xD;
&#xD;
          -  Signs or symptoms of infection requiring treatment with IV antibiotics during the&#xD;
             Screening Period.&#xD;
&#xD;
          -  The participant has fever with body temperature of &gt;=38.5 degree Celsius (ºC) (101.3&#xD;
             degree Fahrenheit [ºF]) at the Screening Visit or before dosing on Day 1.&#xD;
&#xD;
          -  The participant has Acute Chest Syndrome (ACS), diagnosed or strongly suspected, as&#xD;
             evidenced by a new infiltrate on chest radiograph, and one or more of the following&#xD;
             criteria:&#xD;
&#xD;
               1. Fever with body temperature &gt;39°C (102.2°F)&#xD;
&#xD;
               2. Hypoxia (confirmed by arterial blood gases with partial pressure of arterial&#xD;
                  oxygen (PaO2) &lt;70 millimeter of mercury [mmHg])&#xD;
&#xD;
               3. Chest pain&#xD;
&#xD;
               4. Suspicious findings on physical examination (tachypnea, intercostal retraction,&#xD;
                  wheezing, and/or rales)&#xD;
&#xD;
          -  The participant has recently (within the past 28 days, from Screening Visit) undergone&#xD;
             major surgery, requires hospitalization, documented serious bacterial infection&#xD;
             requiring antibiotic treatment, or significant bleeding.&#xD;
&#xD;
          -  The participant has had a recent (within the past 90 days, from Screening Visit)&#xD;
             episode of stroke, transient ischemic attack, symptomatic pulmonary hypertension, or&#xD;
             seizure.&#xD;
&#xD;
          -  Any history of hemorrhagic stroke or bleeding diathesis.&#xD;
&#xD;
          -  The participant has received any of the following protocol-restricted medicines: a)&#xD;
             systemic steroid therapy within 48 hours before dosing, or there is the expectation&#xD;
             that such therapy may be given during the study (inhaled or topical steroids are&#xD;
             allowed); b) Anticoagulant or antiplatelet therapy within the past 3 weeks before&#xD;
             dosing; c) crizanlizumab within the past 30 days before dosing; d) voxelotor within&#xD;
             the past 14 days before dosing.&#xD;
&#xD;
          -  For participants receiving chronic or long-acting opioids, a change in dose or pain&#xD;
             requiring medical attention in the past 14 days before dosing.&#xD;
&#xD;
          -  The participant has a medical or psychiatric condition that, in the opinion of the&#xD;
             investigator, may pose a risk to the participant for participation or interfere with&#xD;
             the conduct or results of the study.&#xD;
&#xD;
          -  The participant has received or plans to receive any other investigational agent&#xD;
             within the 4 weeks prior to the study screening visit or during the course of the&#xD;
             study.&#xD;
&#xD;
          -  There is the expectation that the participant will not be able to be followed for the&#xD;
             duration of the study.&#xD;
&#xD;
          -  The participant is pregnant or lactating or a female of childbearing potential or male&#xD;
             unable or unwilling to comply with birth control methods or abstinence until the end&#xD;
             of study visit.&#xD;
&#xD;
          -  The participant with active use of illicit drugs (excluding marijuana) and/or alcohol&#xD;
             dependence, as determined by the investigator.&#xD;
&#xD;
          -  The participant has been administered SHP655 previously.&#xD;
&#xD;
          -  Known life-threatening hypersensitivity reaction, including anaphylaxis, to the parent&#xD;
             molecule ADAMTS-13, hamster protein, or other constituents of SHP655.&#xD;
&#xD;
          -  The participant has a positive test result for hepatitis B surface antigen, or&#xD;
             hepatitis C antibody, or human immunodeficiency virus (HIV) antigen/antibody, at the&#xD;
             Screening Visit. However, a subject with a hepatitis C antibody and a negative&#xD;
             hepatitis C virus ribonucleic acid (RNA) polymerase chain reaction test is not&#xD;
             excluded.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Takeda Contact</last_name>
    <phone>+1 866 842 5335</phone>
    <email>ClinicalTransparency@takeda.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>205-996-8765</phone>
      <email>jkanter@uabmc.edu</email>
    </contact>
    <investigator>
      <last_name>Julie Kanter Washko, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arkansas Children's Hospital</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>77202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>501-364-1100</phone>
      <email>secrary@uams.edu</email>
    </contact>
    <investigator>
      <last_name>Shelley Crary, MD/MSCS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado Sickle Cell Treatment and Research Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>303-724-9070</phone>
    </contact>
    <investigator>
      <last_name>Kathryn Hassell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sickle Cell Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80262</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>303-724-9071</phone>
      <email>kathryn.hassell@cuanschutz.edu</email>
    </contact>
    <investigator>
      <last_name>Kathryn Hassell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Illinois</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612-4325</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>312-996-5984</phone>
      <email>vgordeuk@uic.edu</email>
    </contact>
    <investigator>
      <last_name>Victor Gordeuk</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center New Orleans</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>504-702-4410</phone>
    </contact>
    <investigator>
      <last_name>Jyotsna Fuloria, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ochsner Health System</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>504-702-4410</phone>
      <email>jyotsna.fuloria@lcmchealth.org</email>
    </contact>
    <investigator>
      <last_name>Jyotsna Fuloria</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University School Of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>410-502-7770</phone>
      <email>slanzkr@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Sophie Lanzkron</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>919-684-2985</phone>
      <email>john.strouse@duke.edu</email>
    </contact>
    <investigator>
      <last_name>John Strouse</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>East Carolina University</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27858</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>252-744-3556</phone>
      <email>lilesd@ecu.edu</email>
    </contact>
    <investigator>
      <last_name>Darla Liles</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>614-293-2887</phone>
      <email>payal.desai@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Payal Desai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina (MUSC)</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site contact</last_name>
      <phone>843-876-0444</phone>
      <email>bergmans@musc.edu</email>
    </contact>
    <investigator>
      <last_name>Shayla Bergmann</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Tennessee -- Memphis</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38163-2116</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>901-448-2813</phone>
      <email>kataga@uthsc.edu</email>
    </contact>
    <investigator>
      <last_name>Kenneth Ataga, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>VCU Health - Research Parent</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>804-828-2161</phone>
      <email>wally.smith@vcuhealth.org</email>
    </contact>
    <investigator>
      <last_name>Wally Smith, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicaltrials.takeda.com/study-detail/5f6b5fe84db2bf003ab47ae1</url>
    <description>To obtain more information on the study, click here/on this link</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 14, 2019</study_first_submitted>
  <study_first_submitted_qc>June 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 25, 2019</study_first_posted>
  <last_update_submitted>August 16, 2021</last_update_submitted>
  <last_update_submitted_qc>August 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_access_criteria>IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://vivli.org/ourmember/takeda/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

